Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia-Reference-Cited by-同舟云学术

Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia

Published:2021-03 Issue:3 Volume:2 Page:340-356
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Hashimoto Mari,Saito Yoriko,Nakagawa Ryo,Ogahara Ikuko,Takagi Shinsuke^ORCID,Takata Sadaaki,Amitani Hanae,Endo Mikiko,Yuki Hitomi^ORCID,Ramilowski Jordan A.,Severin Jessica,Manabe Ri-ichiroh,Watanabe Takashi,Ozaki Kokoro,Kaneko Akiko,Kajita Hiroshi,Fujiki Saera,Sato Kaori,Honma Teruki,Uchida Naoyuki,Fukami Takehiro,Okazaki Yasushi,Ohara Osamu^ORCID,Shultz Leonard D.,Yamada Makoto,Taniguchi Shuichi,Vyas Paresh,de Hoon Michiel,Momozawa Yukihide,Ishikawa Fumihiko^ORCID

Funder

MEXT | RIKEN

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s43018-021-00177-w.pdf

Reference69 articles.

1. Tallman, M. S., Gilliland, D. G. & Rowe, J. M. Drug therapy for acute myeloid leukemia. Blood 106, 1154–1163 (2005).

2. DiNardo, C. D. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 378, 2386–2398 (2018).

3. Perl, A. E. et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl. J. Med. 381, 1728–1740 (2019).